Monday, May 25, 2026
ISSN 2765-8767
  • Survey
  • Podcast
  • Write for Us
  • My Account
  • Log In
Daily Remedy
  • Home
  • Articles
  • Podcasts
    How NADAC, WAC, and ASP Shape Drug Costs

    How NADAC, WAC, and ASP Shape Drug Costs

    April 20, 2026
    The Hidden Costs Employers Don’t See in Traditional Health Plans

    The Hidden Costs Employers Don’t See in Traditional Health Plans

    March 22, 2026
    The Impact of COVID-19 on Patient Trust

    The Impact of COVID-19 on Patient Trust

    March 3, 2026
    Debunking Myths About GLP-1 Medications

    Debunking Myths About GLP-1 Medications

    February 16, 2026
    The Future of LLMs in Healthcare

    The Future of LLMs in Healthcare

    January 26, 2026
    The Future of Healthcare Consumerism

    The Future of Healthcare Consumerism

    January 22, 2026
  • Surveys

    Surveys

    Public Perception of Peptide Regulation and Compounding Practices

    Public Perception of Peptide Regulation and Compounding Practices

    April 19, 2026
    Understanding of Clinical Evidence in Peptide and Hormone Use

    Understanding of Clinical Evidence in Peptide and Hormone Use

    March 30, 2026

    Survey Results

    Can you tell when your provider does not trust you?

    Can you tell when your provider does not trust you?

    January 18, 2026
    Do you believe national polls on health issues are accurate

    National health polls: trust in healthcare system accuracy?

    May 8, 2024
    Which health policy issues matter the most to Republican voters in the primaries?

    Which health policy issues matter the most to Republican voters in the primaries?

    May 14, 2024
    How strongly do you believe that you can tell when your provider does not trust you?

    How strongly do you believe that you can tell when your provider does not trust you?

    May 7, 2024
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Official Learner
No Result
View All Result
  • Home
  • Articles
  • Podcasts
    How NADAC, WAC, and ASP Shape Drug Costs

    How NADAC, WAC, and ASP Shape Drug Costs

    April 20, 2026
    The Hidden Costs Employers Don’t See in Traditional Health Plans

    The Hidden Costs Employers Don’t See in Traditional Health Plans

    March 22, 2026
    The Impact of COVID-19 on Patient Trust

    The Impact of COVID-19 on Patient Trust

    March 3, 2026
    Debunking Myths About GLP-1 Medications

    Debunking Myths About GLP-1 Medications

    February 16, 2026
    The Future of LLMs in Healthcare

    The Future of LLMs in Healthcare

    January 26, 2026
    The Future of Healthcare Consumerism

    The Future of Healthcare Consumerism

    January 22, 2026
  • Surveys

    Surveys

    Public Perception of Peptide Regulation and Compounding Practices

    Public Perception of Peptide Regulation and Compounding Practices

    April 19, 2026
    Understanding of Clinical Evidence in Peptide and Hormone Use

    Understanding of Clinical Evidence in Peptide and Hormone Use

    March 30, 2026

    Survey Results

    Can you tell when your provider does not trust you?

    Can you tell when your provider does not trust you?

    January 18, 2026
    Do you believe national polls on health issues are accurate

    National health polls: trust in healthcare system accuracy?

    May 8, 2024
    Which health policy issues matter the most to Republican voters in the primaries?

    Which health policy issues matter the most to Republican voters in the primaries?

    May 14, 2024
    How strongly do you believe that you can tell when your provider does not trust you?

    How strongly do you believe that you can tell when your provider does not trust you?

    May 7, 2024
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Official Learner
No Result
View All Result
Daily Remedy
No Result
View All Result
Home Perspectives

Even after Lockdowns Eased, Pandemic Depression Persisted Across Social Classes

The Conversation by The Conversation
April 3, 2024
in Perspectives
0
Even after Lockdowns Eased, Pandemic Depression Persisted Across Social Classes

Even after lockdowns eased, pandemic depression persisted across social classes – new study

window view
The high and persistent prevalence of depression suggests that mental illness increased for all social classes during the COVID-19 pandemic.
piola666/E+ via Getty Images

Catherine Ettman, Boston University and Sandro Galea, Boston University

The Research Brief is a short take about interesting academic work.

The big idea

One year into the COVID-19 pandemic, we found that more than 1 in 5 U.S. adults reported probable depression in both spring 2020 and spring 2021. We also found that financial assets helped reduce the persistence of symptoms – but only to a point. Our recently published research highlights COVID-19’s continuing mental health effects on the U.S. population.

We launched a national study in March 2020 measuring mental health and assets. COVID-19 was a national emergency, as deaths were on the rise. Schools, workplaces and government offices closed as Americans were urged to stay home. At that time, we found that 27.8% of U.S. adults in our study reported symptoms of depression, such as losing interest in activities or feeling down or hopeless. This number was over three times as high as the national pre-pandemic depression estimate of 8.5%.

Woman wearing a surgical mask sits on the steps of an office building, resting her elbow on a bent knee holding her forehead, with her purse and work binder beside her.
A new study finds that depression increased for all social classes during the COVID-19 pandemic.
boy_anupong/Moment via Getty Images

Most striking to us was that a year into the pandemic, depression rates remained high, despite hopeful signs of reducing infections and deaths. In April 2021, people were lining up for COVID-19 vaccine shots, doctors were finding better COVID-19 treatments and efforts to reopen society were under way. But by that point, the share of adults in our survey reporting symptoms of depression had gone up to 32.8%.

Worse yet, that higher 2021 number included 20.3% who had reported symptoms of depression both in April 2020 and in April 2021. This finding suggests that poor mental health driven by the pandemic was both prevalent and persistent.

We also wanted to know which assets – financial, physical and social – might be influencing people’s mental health during the pandemic. In our first survey, we found that people who came into the pandemic with relatively few assets – especially financial ones – were more likely to be affected by COVID-19-related stresses.

In our April 2021 follow-up survey, we were interested in the relationship between mental health and asset status. We looked at financial assets such as personal savings, physical assets such as home ownership and social assets of education and marital status. We compared people who were similar in terms of marriage, education and home ownership. We found that people in households earning less than US$20,000 a year were 3.5 times as likely to report persistent depression symptoms as those making $75,000.

We also found that people who had $5,000 or more in savings or a bank account reported less persistent depression. Having more assets, however, did not reduce the depression-inducing stress of losing a job, suffering relationship problems or experiencing financial difficulties during the pandemic.

Why it matters

Nearly 1 million U.S. lives have been lost to COVID-19, and there have been almost 5 million hospitalizations. But measuring the effect of the pandemic on the nation’s mental health is just beginning. And we believe the pandemic’s sustained impact on the nation’s mental health is unprecedented.

What’s next

Our next move is to further examine areas of overlap between those who started the pandemic with fewer assets and those who suffered job losses, relationship problems or financial difficulties during the pandemic.

People who have fewer assets are the ones most at risk of depression, especially depression that lasts over time with social upheaval. Assets can be a cushion, but even they did not protect people from the harmful effects of stressors brought on by the pandemic. Our research shows that although the pandemic seems to be easing, Americans are still suffering. And they may continue to feel ill effects on their mental health for a long time to come.

[Get fascinating science, health and technology news. Sign up for The Conversation’s weekly science newsletter.]

Catherine Ettman, PhD Candidate, Boston University and Sandro Galea, Professor of Family Medicine, Boston University

This article is republished from The Conversation under a Creative Commons license. Read the original article.

ShareTweet
The Conversation

The Conversation

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Videos

summary

An in-depth exploration of drug pricing, including key databases like NADAC, WAC, and ASP, and how they influence the pharmaceutical supply chain, policy, and patient advocacy. The episode also introduces MedPricer's innovative pricing intelligence platform, offering valuable insights for healthcare professionals, policymakers, and patients.

Chapters

00:00 Understanding Drug Pricing Dynamics
03:52 Exploring the Drug Pricing Database
10:07 Patient Advocacy and Drug Pricing
13:56 Market Intelligence in Drug Pricing
How NADAC, WAC, and ASP Shape Drug CostsDaily Remedy
YouTube Video X-Tfwy7XKEg
Subscribe

Policy Shift in Peptide Regulation

Clinical Reads

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

by Daily Remedy
April 19, 2026
0

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!

Twitter Updates

Tweets by TheDailyRemedy

Popular

  • The IRA’s Drug Negotiation Mechanism Meets the Rebate Industrial Complex

    The IRA’s Drug Negotiation Mechanism Meets the Rebate Industrial Complex

    0 shares
    Share 0 Tweet 0
  • Two Platforms, Two Theories of Change in Hospital Pricing

    0 shares
    Share 0 Tweet 0
  • The Payer’s Dilemma: Choosing Between Negotiation Intelligence and Market Disclosure

    0 shares
    Share 0 Tweet 0
  • Growth Hormone Secretagogues and the Longevity Trade-Off

    0 shares
    Share 0 Tweet 0
  • Infinite Clinical Games

    0 shares
    Share 0 Tweet 0
  • 628 Followers

Daily Remedy

Daily Remedy offers the best in healthcare information and healthcare editorial content. We take pride in consistently delivering only the highest quality of insight and analysis to ensure our audience is well-informed about current healthcare topics - beyond the traditional headlines.

Daily Remedy website services, content, and products are for informational purposes only. We do not provide medical advice, diagnosis, or treatment. All rights reserved.

Important Links

  • Support Us
  • About Us
  • Contact us
  • Privacy Policy
  • Terms and Conditions

Join Our Newsletter!

  • Survey
  • Podcast
  • About Us
  • Contact us

© 2026 Daily Remedy

No Result
View All Result
  • Home
  • Articles
  • Podcasts
  • Surveys
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Official Learner

© 2026 Daily Remedy